A5004661714- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- T-cell and Retrovirus Studies
- Mesenchymal stem cell research
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Histone Deacetylase Inhibitors Research
- Transplantation: Methods and Outcomes
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Gestational Trophoblastic Disease Studies
- Biosimilars and Bioanalytical Methods
- CNS Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Cytomegalovirus and herpesvirus research
- Cancer Immunotherapy and Biomarkers
Anhui Provincial Hospital
2014-2024
University of Science and Technology of China
2018-2024
Zhejiang University of Technology
2024
Second Affiliated Hospital of Zhejiang University
2023
Anhui Medical University
2010-2023
Memorial University of Newfoundland
2023
Tongji Hospital
2023
First Affiliated Hospital of Henan University of Science and Technology
2022
Second Military Medical University
2009
Changhai Hospital
2009
Abstract Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphoma (SLL). This single‐arm, multi‐center, open‐label, phase 2 80 eligible Chinese patients, who were treated monotherapy orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee primary...
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin with limited treatment options. This phase II study evaluated the efficacy safety sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL.Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months until progression, death, withdrawal. The primary end point was objective response rate (ORR) assessed by independent radiologic...
Castleman disease (CD) is a group of rare and heterogenous lymphoproliferative disorders including unicentric CD (UCD), human herpesvirus-8(HHV-8)-associated multicentric (HHV8-MCD), HHV-8-negative/idiopathic (iMCD). Knowledge mainly comes from case series or retrospective studies, but the inclusion criteria these studies vary because Disease Collaborative Network (CDCN) diagnostic for iMCD UCD were not available until 2017 2020, respectively. Further, guidelines have been systematically evaluated.
8025 Background: CT103A, which is designed with a fully human BCMA-specific CAR structure, has shown sustained efficacy and durable safety in heavily pretreated relapsed refractory multiple myeloma patients. Here, we report updated data of its phase 1b/2 study (FUMANBA-1) longer duration follow-up. Methods: FUMANBA-1 conducted 14 centers China. This enrolled RRMM patients who received ≥ 3 lines prior therapies containing at least proteasome inhibitor an immunomodulatory agent were to their...
Relapsed or refractory (r/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) mediator of receptor signaling and associated the development lymphomas. Patients r/r MCL were enrolled in this phase 1/2 study treated orelabrutinib, novel, highly selective BTK inhibitor. The median number prior regimens was 2 (range, 1-4). age 62 years 37-73 years). Eligible patients received oral orelabrutinib 150 mg once daily (n = 86) 100 twice...
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 December 2017, 548 R/R from 186 research centers China were included study. Among 261 treated chidamide monotherapy, ORR 58.6% 55 (21.1%) achieved complete (CR). 287 receiving chidamide-containing...
Drinking water is an important natural resource. For many people worldwide, especially in developing countries, access to safe drinking still a dream. An increasing number of human activities and industrialization have caused various physical, chemical, biological pollutants enter bodies, affecting health. Water contain vast additives, such as perfluorinated chemicals, polybrominated diphenyl ethers, phthalate, nanomaterials, insecticides, microcystins, heavy metals, pharmacologies. In this...
Abstract Pre‐engraftment syndrome (PES) after umbilical cord blood transplantation (CBT) remains poorly characterized, and the prognosis appropriate management are unclear. Therefore, we retrospectively analyzed incidence, risk factors, manifestations, clinical outcomes of PES in CBT recipients, who had been treated for hematologic malignancies at our center. was defined as unexplained fever higher than 38.3°C that is not associated with documented infection unresponsive to antimicrobial...
Abstract The induction therapy containing ixazomib, an oral proteasome inhibitor, has shown favorable efficacy and safety in clinical trials, but its experience real-life remains limited. In routine practice, few patients received ixazomib-based due to reasons including (1) patients’ preference on regimens, (2) concerns adverse events (AEs) of other intravenous/subcutaneous (3) requirements for less center visits, (4) fears COVID-19 infectious disease exposures. With the aim assessing...
The circadian clock is crucial in plant immunity and metabolism, yet the coordinating mechanisms remain elusive. In present study, transcriptome analysis of M. oryzae-infected rice leaves rhythmic showed reduced amplitudes phytochrome genes, impacting immune response, metabolic pathways, calcium signaling. pattern-triggered (PTI)-related genes declined, while rhythmicity effector-triggered (ETI)-related disappeared. Moreover, alterations phases pathways were observed, potentially involved...
Background Nearly all anti-PD-1 antibodies are of the IgG4 isotype, and thus possess residual FcR effector functions. Such also associated with immune tolerance escape due to instability CH3 domain Fc-Fc interaction. In this trial, we examined efficacy safety penpulimab, a novel IgG1 antibody that does not bind Fc receptor, in patients refractory or relapsed classical Hodgkin lymphoma (R/R cHL). Methods Adult (≥18 years age) R/R cHL received 200 mg penpulimab once biweekly until disease...
MALT lymphoma is an extranodal B-cell of the marginal zone mucosa-associated lymphoid tissue (MALT), caused by malignant transformation B-cells in zone. In this work, we aim to explore potential relationship between and DLBCL. Vaccines derived from messenger ribonucleic acid (mRNA) may provide satisfactory results. Despite being a promising treatment option, immunotherapy isn't widely used treating renal cell carcinoma, as only few patients respond treatment. The Cancer Genome Atlas (TCGA)...